General Stock Ideas

[gfp927z]

Hi SC, Looks like CTIX is now 'IPIX', after changing their name to 'Innovation Pharma' last week (see below). I haven't followed them for a while so will need to get back up to speed.

The antibiotic that I was mainly interested in (Brilacidin) was progressing successfully into some non-antibiotic indications (Oral Mucositis and Ulcerative Proctitis), but the planned Phase 3 for ABSSSI (MRSA skin infections) had yet to be started. The last I checked the indication seemed to have been put on the back burner on the company's list of priorities. Their other programs (Kevetrin and Prurisol, for cancer and psoriasis respectively) I'm not that familiar with.

For Brilacidin, the Oral Mucositis indication is actually a large market. It turns out that Brilacidin's unique defensin mimetics mechanism (which mimics the body's own defensin protein system), has strong anti-inflammatory activity and works great for Oral Mucositis, which can be a severe complication in some cancer patients undergoing chemo. The lining of the mouth (oral mucosa) gets so inflamed that in some cases they can't eat and have to go on an IV feeding tube. Brilacidin has amazing efficacy in reversing the inflammation, and they also have it in Phase 2 for another inflammatory condition, Ulcerative Proctitis.

So even without the antibiotic indications, Brilacidin could be a big success due to its potent anti-inflammatory properties, and is thus a potential platform technology for many inflammatory related conditions. So definitely something worth following.

Being ever the conspiracy theorist, I always figured the Deep State would try to deep six Brilacidin as an antibiotic, since it has the potential to cure most of the world's bacterial infections, due to its mimicking of the body's own natural defensin protein system. We know the 'cabal' is obsessed with overpopulation, so this is they type of breakthough they would want to keep away from the general public (us) who they consider useless eaters.




http://investorshub.advfn.com/boards/read_msg.aspx?message_id=131992095


>>> BEVERLY, Mass., June 7, 2017 (GLOBE NEWSWIRE) -- Cellceutix Corporation, (OTCQB:CTIX) (“the Company”), an emerging biopharmaceutical company, is pleased to announce to shareholders, and the public at large, that it is changing its name to Innovation Pharmaceuticals Inc. (IPI) and has received a new Committee on Uniform Securities Identification Procedures (CUSIP) number of 45782D 100.

Innovation Pharmaceuticals more accurately describes the innovative nature of our first-in-class pipeline of mid-stage drug candidates. These changes will have no impact on the marketability of the Company’s securities, or the ability to trade the common stock through brokerage firms. Stockholders of the Company are not required to exchange their stock certificates in connection with the name change.

The Company’s common stock will continue to trade under stock symbol “CTIX” on OTCQB until market close on June 8, 2017. Trading on the OTCQB under the new Innovation Pharmaceuticals name and ticker symbol “IPIX” will begin at market open on June 9, 2017.

The Company’s new website address will change to www.IPharmInc.com. In the interim, the Company will maintain www.cellceutix.com.

The name change will be discussed at the upcoming live shareholder and investor conference call, to be held on Thursday, June 8, 2017, at 11am EDT. Senior Company management will be responding to recently posed questions submitted by email. Live call-in questions will also be addressed.

Below are call-in details for the conference call:

Title: Innovation Pharmaceuticals Shareholder and Investor Conference Call

Presentation Type: Audio Webcast
Event Date: Thursday, June 8, 2017, at 11am EDT
Call-in Numbers: 866-682-6100 / 862-255-5401
Event Link: http://www.investorcalendar.com/event/15776

<<<